NASDAQ$SXTC
China SXT Pharmaceuticals Inc. · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Headline financials
Revenue & EPS history
China SXT · Revenue · Quarterly
$2.6M
Q4 2022-45.5%vs Q4 2021
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 13 quarterly earnings reports · overlaid with Q4 2022
-5.7%
Avg return
Earnings day
-14.5%
Avg return
5 days after
-25.4%
Avg return
30 days after
23%
3 / 13 earnings
Positive
+20.4%
Q2 2020
Best reaction
-59.0%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2024 | -1.0% | -1.9% | -36.5% | |
| Q4 2023 | -1.0% | -100.0% | -100.0% | |
| Q2 2023 | -6.9% | -4.9% | -30.6% | |
| Q4 2022 | +2.7% | -13.4% | -17.1% | |
| Q2 2022 | -59.0% | -62.8% | -65.4% | |
| Q4 2021 | -10.5% | -9.7% | -10.5% | |
| Q2 2021 | +3.6% | +0.8% | +11.0% | |
| Q4 2020 | -6.7% | -1.2% | -25.0% | |
| Q2 2020 | +20.4% | +15.6% | +13.7% | |
| Q4 2019 | -5.0% | -4.8% | -18.6% | |
| Q4 2018 | -5.0% | -4.8% | -18.6% | |
| Q4 2017 | -5.0% | -4.8% | -18.6% | |
| Q2 2019 | -0.5% | +3.6% | -14.0% | |
| Q3 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro